Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis

Life Sciences

Volumn 80, Issue 5, 2007, Pages 484-492

  Zhao, Qing Tao ^a,b   Yue, Shu Qiang ^a   Cui, Zhong ^b   Wang, Qi ^c   Cui, Xin ^b   Zhai, Hui Hong ^d   Zhang, Li Hui ^b   Dou, Ke Feng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b BETHUNE INTERNATIONAL PEACE HOSPITAL   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Cox 2 inhibitor; Cyclooxygenase 2; HCC; siRNA

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FIBROBLAST GROWTH FACTOR 2; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; SMALL INTERFERING RNA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; UMBILICAL VEIN;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN; CULTURE MEDIA, CONDITIONED; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DRUG COMBINATIONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LAMININ; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 33845875713     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.09.038     Document Type: Article

References (52)

1. Abou-Shady M., Baer H.U., Friess H., Zimmermann A., and Buchler M.W. Molecular aspects of hepatocellular carcinoma. Swiss Surgery 5 3 (1999) 102-106
2. Amano H., Haysahi I., Yoshida S., Yoshimura H., and Majima M. Cyclooxygenase-2 and adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Human Cell 15 1 (2002) 13-24
3. Brummelkamp T.R., Bernards R., and Agami1 R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296 5567 (2002) 550-553
4. Cheng A.S., Chan H.L., To K.F., Leung W.K., Chan K.K., Liew C.T., and Sung J.J. Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. International Journal of Oncology 24 4 (2004) 853-860
5. Chu J., Lloyd F.L., Trifan O.C., Knapp B., and Rizzo M.T. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Molecular Cancer Therapeutics 2 1 (2003) 1-7
6. Cianchi F., Cortesini C., Bechi P., Fantappie O., Messerini L., and Vannacci A. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 121 6 (2001) 1339-1347
7. αVâ3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. The Journal of Biological Chemistry 277 48 (2002) 45838-45846
8. El-Serag H.B., Mason A.C., and Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the Unites States. Hepatology 33 1 (2001) 62-65
9. Elbashir S.M., Harborth J., Weber K., and Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26 (2002) 199-213
10. Folkman J. What is the evidence that tumors are angiogenesis dependent?. Journal of the National Cancer Institute 82 1 (1990) 4-6
11. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1 1 (1995) 27-31
12. Fu Y.G., Sung J.J., Wu K.C., Wu H.P., Yu J., Chan M., Chan V.Y.M., Chan K.K., Fan D.M., and Leung W.K. Inhibition of gastric cancer-associated angiogenesis by antisense COX-2 transfectants. Cancer Letters 224 2 (2005) 243-252
13. Gallo O., Franchi A., Magnelli L., Sardi I., Vannacci A., Boddi V., Chiarugi V., and Masini E. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. implications for tumor angiogenesis and metastasis. Neoplasia 3 1 (2001) 53-61
14. Han C., Michalopoulos G., and Wu T. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. Journal of Cellular Physiology 207 1 (2006) 261-270
15. Hla T., and Neilson K. Human cyclooxygenase-2 cDNA. Proceedings of the National Academy of Sciences of the United States of America 89 16 (1992) 7384-7388
16. Hu K.Q. Rationale and feasibility of chemoprevention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. Journal of Laboratory and Clinical Medicine 139 4 (2002) 234-243
17. Iniguez M.A., Rodríguez A., Volpert O.V., Fresno M., and Redondo J.M. Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends in Molecular Medicine 9 2 (2003) 73-78
18. Jee S.H., Chu C.Y., Chiu H.C., Huang Y.L., Tsai W.L., Liao Y.H., and Kuo M.L. Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-Kinase/Akt pathways. The Journal of Investigative Dermatology 123 6 (2004) 1169-1175
19. Jones D.A., Carlton D.P., McIntyre T.M., Zimmerman G.A., and Prescott S.M. Molecular cloning of human prostaglandin endoperoxide synthase type and demonstration of expression in response to cytokines. The Journal of Biological Chemistry 268 12 (1993) 9049-9054
20. Kasai A., Shintani N., Oda M., Kakuda M., Hashimoto H., Matsuda T., Hinuma S., and Baba A. Apelin is a novel angiogenic factor in retinal endothelial cells. Biochemical and Biophysical Research Communications 325 2 (2004) 395-400
21. Kawamori T., Rao C.V., Seibert K., and Reddy B.S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Research 58 3 (1998) 409-412
22. Kern A.M., Schubert D., Sahi D., Schöneweiss M.M., Moll I., Haugg A.M., Dienes P.H., Breuhahn K., and Schirmacher P. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 36 4 pt 1 (2002) 885-894
23. Koga H. Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?. Cancer 98 4 (2003) 661-667
24. Koga H., Sakisaka S., Ohishi M., Kawaguchi J., Taniguchi E., Sasatomi K., Howada M., Kusaba T., Tanaka M., Kimura R., Nakashima Y., Nakashima O., Kojiro M., Kurohiji T., and Sata M. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor differentiation. Hepatology 29 3 (1999) 688-696
25. Kondo M., Yamamoto H., Nagano H., Okami J., Ito Y., Shimizu J., Eguchi H., Miyamoto A., Dono K., Umeshita K., Matsuura N., Wakasa K., Nakamori S., Sakon M., and Monden M. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clinical Cancer Research 5 2 (1999) 4005-4012
26. Krysan K., Merchant F.H., Zhu L., Dohadwala M., Luo J., and Lin Y. Cox-2-dependent stabilization of survivin in non-small cell lung cancer. Federation of American Societies for Experimental Biology 18 1 (2004) 206-208
27. Labayle D., Fischer D., Vielh P., Drouhin F., Pariente A., Bories C., Duhamel O., Trousset M., and Attali P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101 3 (1991) 635-639
28. Lee Y.S., Yang H.O., Shin K.H., Choi H.S., Jung S.H., Kim Y.M., Oh D.K., Linhardt R.J., and Kim Y.S. Suppression of tumor growth by a new glycosaminoglycan isolated from the African giant snail Achatina fulica. European Journal of Pharmacology 465 1-2 (2003) 191-198
29. Lee A., Frischer J., Serur A., Huang J., Bae J.O., Kornfield Z.N., Eljuga L., Shawber C.J., Feirt N., Mansukhani M., Stempak D., Baruchel S., Bender J.G., Kandel J.J., and Yamashiro D.J. Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling. Cancer Research 66 8 (2006) 4378-4384
30. Leung W.K., Bai A.H., Chan V.Y., Yu J., To K.F., and Wu J.R. Effect of peroxisome proliferators-activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells. Gut 53 3 (2004) 331-338
31. Li G., Yang T., and Yan J. Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochemical and Biophysical Research Communications 299 5 (2002) 886-890
32. Liu C.H., Chang S.H., Narko K., Trifan O.C., Wu M.T., and Smith E. Over-expression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. The Journal of Biological Chemistry 276 21 (2001) 18563-18569
33. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., and Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Research 60 5 (2000) 1306-1311
34. Mayoral R., Fernández-Martínez A., Boscá L., and Martín-Sanz P. Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells. Carcinogenesis 26 4 (2005) 753-761
35. Molina M.A., Sitja-Arnau M., Lemoine M.G., Frazier M.L., and Sinicrope F. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Research 59 17 (1999) 4356-4362
36. Morinaga S., Yamamoto Y., Noguchi Y., Imada T., Rino Y., Akaike M., Sugimasa Y., Takemiya S., Kameda Y., and Takanashi Y. Cyclooxygenase-2 mRNA is up-regulated in cirrhotic or chronic hepatitis liver adjacent to hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 17 10 (2002) 1110-1116
37. Namkoong S., Lee S.J., Kim C.K., Kim Y.M., Chung H.T., Lee H., Han J.A., Ha K.S., Kwon Y.G., and Kim Y.M. Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells. Experimental and Molecular Medicine 37 6 (2005) 588-600
38. Ochiai M., Oguri T., Isobe T., Ishioka S., and Yamakido M. Cyclooxygenase-2 mRNA expression levels in normal lung tissues and non-small cell lung cancers. Japanese Journal of Cancer Research 90 12 (1999) 1338-1343
39. Oshima M., Dinchuk J.E., Kragman S.L., Oshima H., Hanock B., Kwong E., Trzaskos J.M., Evans J.F., and Taketo M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase-2 (Cox-2). Cell 87 5 (1996) 803-809
40. Pai R., Szabo I.L., Soreghan B.A., Atay S., Kawanaka H., and Tarnawski A.S. PGE2 stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochemical and Biophysical Research Communications 286 5 (2001) 923-928
41. Poon R.T., Ng I.O., Lau C., Yu W.C., Yang Z.F., Fan S.T., and Wong J. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. Journal of Clinical Oncology 20 7 (2002) 1775-1785
42. Rahman M.A., Dhar D.K., Yamaguchi E., Maruyama S., Sato T., Hayashi H., Ono T., Yamanoi A., Kohno H., and Nagasue N. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus positive cases. Clinical Cancer Research 7 5 (2001) 1325-1332
43. Ramesh R., Mhashilkar A.M., Tanaka F., Saito Y., Branch C.D., Sieger K., Mumm J.B., Stewart A.L., Boquio A., Dumoutier L., Grimm E.A., Renauld J.C., Kotenko S., and Chada S. Melanoma differentiation-associated gene 7/Interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Research 63 16 (2003) 5105-5113
44. Sano H., Kawahito Y., Wilder R.L., Hashiramoto A., Mukai S., Asai K., Kimuva S., Kouto H., Kondo M., and Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Research 55 17 (1995) 3785-3789
45. Song X., Lin H.P., Johnson A.J., Tseng P.H., Yang Y.T., and Kulp S.K. Cyclooxygenase-2 player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. Journal of the National Cancer Institute 94 8 (2002) 585-591
46. Sonoshita M., Takaku K., Sasaki N., Sugimoto Y., Ushikubi F., and Narumiya S. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcDelta716 knockout mice. Nature Medicine 7 9 (2001) 1048-1051
47. Spinella F., Rosano L., Di Castro V., Natali P.G., and Bagnato A. Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. The Journal of Biological Chemistry 279 45 (2004) 46700-46705
48. Tamura K., Sakurai T., and Kogo H. Relationship between prostaglandin E2 and vascular endothelial growth factor (VEGF) in angiogenesis in human vascular endothelial cells. Vascular Pharmacology 44 6 (2006) 411-416
49. Tang T.C., Poon R.T., Lau C.P., Xie D., and Fan S.T. Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World Journal of Gastroenterology 11 13 (2005) 1896-1902
50. Tanigawa N., Lu C., Mitsui T., and Miura S. Quantitation of sinusoid-like vessels in hepatocellular carcinoma: its clinical and prognostic significance. Hepatology 26 5 (1997) 1216-1223
51. Wang D., Wang H., Brown J., Daikoku T., Ning W., Shi Q., Richmond A., Strieter R., Dey S.K., and DuBois R.N. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. The Journal of Experimental Medicine 203 4 (2006) 941-951
52. Yoysungnoen P., Wirachwong P., Bhattarakosol P., Niimi H., and Patumraj S. Effects of curcumin on tumor angiogenesis and biomarkers, Cox-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. Clinical Hemorheology and Microcirculation 34 1-2 (2006) 109-115